JP2020532538A - 治療用金属錯体およびリガンドならびにその作成および使用の方法 - Google Patents

治療用金属錯体およびリガンドならびにその作成および使用の方法 Download PDF

Info

Publication number
JP2020532538A
JP2020532538A JP2020512506A JP2020512506A JP2020532538A JP 2020532538 A JP2020532538 A JP 2020532538A JP 2020512506 A JP2020512506 A JP 2020512506A JP 2020512506 A JP2020512506 A JP 2020512506A JP 2020532538 A JP2020532538 A JP 2020532538A
Authority
JP
Japan
Prior art keywords
aliphatic
aryl
heteroaliphatic
heteroaryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020512506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532538A5 (enExample
Inventor
ビュードライ クリス
ビュードライ クリス
ハースト ジェームス
ハースト ジェームス
ベックマン ジョセフ
ベックマン ジョセフ
シロイス ジョン
シロイス ジョン
Original Assignee
オレゴン ステイト ユニバーシティー
オレゴン ステイト ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレゴン ステイト ユニバーシティー, オレゴン ステイト ユニバーシティー filed Critical オレゴン ステイト ユニバーシティー
Publication of JP2020532538A publication Critical patent/JP2020532538A/ja
Publication of JP2020532538A5 publication Critical patent/JP2020532538A5/ja
Priority to JP2023160601A priority Critical patent/JP2024001064A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/08—Copper compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020512506A 2017-09-01 2018-08-31 治療用金属錯体およびリガンドならびにその作成および使用の方法 Pending JP2020532538A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023160601A JP2024001064A (ja) 2017-09-01 2023-09-25 治療用金属錯体およびリガンドならびにその作成および使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553714P 2017-09-01 2017-09-01
US62/553,714 2017-09-01
PCT/US2018/049163 WO2019046761A1 (en) 2017-09-01 2018-08-31 THERAPEUTIC METAL COMPLEXES AND LIGANDS, METHODS OF MAKING AND USING SAME

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023160601A Division JP2024001064A (ja) 2017-09-01 2023-09-25 治療用金属錯体およびリガンドならびにその作成および使用の方法

Publications (2)

Publication Number Publication Date
JP2020532538A true JP2020532538A (ja) 2020-11-12
JP2020532538A5 JP2020532538A5 (enExample) 2021-10-07

Family

ID=63684510

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512506A Pending JP2020532538A (ja) 2017-09-01 2018-08-31 治療用金属錯体およびリガンドならびにその作成および使用の方法
JP2023160601A Pending JP2024001064A (ja) 2017-09-01 2023-09-25 治療用金属錯体およびリガンドならびにその作成および使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023160601A Pending JP2024001064A (ja) 2017-09-01 2023-09-25 治療用金属錯体およびリガンドならびにその作成および使用の方法

Country Status (8)

Country Link
US (2) US11596651B2 (enExample)
EP (1) EP3676271A1 (enExample)
JP (2) JP2020532538A (enExample)
CN (1) CN111278835A (enExample)
AU (1) AU2018325283B2 (enExample)
CA (1) CA3074258A1 (enExample)
IL (1) IL272895B2 (enExample)
WO (1) WO2019046761A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024001064A (ja) * 2017-09-01 2024-01-09 オレゴン ステイト ユニバーシティー 治療用金属錯体およびリガンドならびにその作成および使用の方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022001037A (es) * 2019-07-25 2022-07-19 Als Therapy Development Inst Cuptsm para el tratamiento de trastornos neurodegenerativos.
AR123360A1 (es) * 2020-08-26 2022-11-23 Als Therapy Development Inst Complejos de cobre para el tratamiento de trastornos neurodegenerativos

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061306A1 (en) * 2006-11-20 2008-05-29 The University Of Melbourne Metal delivery agents and therapeutic uses of the same
JP2012511513A (ja) * 2008-12-12 2012-05-24 ザ ユニバーシティ オブ メルボルン 非対称性ビス（チオセミカルバゾン）の調製方法
JP2016540828A (ja) * 2013-11-11 2016-12-28 コラボレイティブ メディシナル デベロップメント， エルエルシー 金属錯体および処置方法
WO2017070752A1 (en) * 2015-10-29 2017-05-04 The University Of Queensland Imaging agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7403524A (en) 1959-09-15 1974-05-27 Pharmaceutical compsn. - contg. alpha-dithiosemicarbazone active against trichomonas vaginalis
US4107210A (en) 1976-09-07 1978-08-15 The Dow Chemical Company Synthesis of alpha-diketones
CA2166676C (en) * 1995-01-09 2007-05-01 Yasuhisa Fujibayashi Diagnostic agent for hypoxia or mitochondrial dysfunction comprising radioactive copper complex of dithiosemicarbazone derivative or diamine diol schiff base derivative
GB0617299D0 (en) * 2006-09-01 2006-10-11 Isis Innovation Compounds for imaging and therapy
WO2017214546A1 (en) * 2016-06-10 2017-12-14 University Of Louisville Research Foundation, Inc. Compounds, related compositions, catalysts, electrochemical cells, fuel cells, their preparation and their uses
WO2018204564A1 (en) * 2017-05-04 2018-11-08 University Of Louisville Research Foundation, Inc. Thiosemicarbazone derivatives as anti-cancer agents
IL272895B2 (en) * 2017-09-01 2025-06-01 Univ Oregon State Therapeutic metal complexes and ligands and methods of making and using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061306A1 (en) * 2006-11-20 2008-05-29 The University Of Melbourne Metal delivery agents and therapeutic uses of the same
JP2012511513A (ja) * 2008-12-12 2012-05-24 ザ ユニバーシティ オブ メルボルン 非対称性ビス（チオセミカルバゾン）の調製方法
JP2016540828A (ja) * 2013-11-11 2016-12-28 コラボレイティブ メディシナル デベロップメント， エルエルシー 金属錯体および処置方法
WO2017070752A1 (en) * 2015-10-29 2017-05-04 The University Of Queensland Imaging agents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALSOP, LIAM; COWLEY, ANDREW R.; DILWORTH, JONATHAN R.; DONNELLY, PAUL S.; PEACH, JOSEPHINE M.; RIDER: "Investigations into some aryl substituted bis(thiosemicarbazones) and their copper complexes", INORGANICA CHIMICA ACTA, vol. Vol.358(9), JPN6022042290, 2005, pages 2770 - 2780, ISSN: 0005224223 *
COWLEY, ANDREW R.; DILWORTH, JONATHAN R.; DONNELLY, PAUL S.; HESLOP, JULIA M.; RATCLIFFE, STEVEN J.: "Bifunctional chelators for copper radiopharmaceuticals: the synthesis of [Cu(ATSM)-amino acid] and [", DALTON TRANSACTIONS, vol. 2, JPN6022042293, 2007, pages 209 - 217, ISSN: 0005224225 *
DEARLING, JASON L. J.; BLOWER, PHILIP J.: "Redox-active metal complexes for imaging hypoxic tissues: structure-activity relationships in copper", CHEMICAL COMMUNICATIONS (CAMBRIDGE), vol. 22, JPN6022042298, 1998, pages 2531 - 2532, ISSN: 0005224229 *
DURACKOVA, ZDENA; MENDIOLA, MA. ANTONIA; SEVILLA, MA. TERESA; VALENT, ALADAR: "Thiohydrazone copper(II) complexes. The relationship between redox properties and superoxide dismuta", BIOELECTROCHEMISTRY AND BIOENERGETICS, vol. Vol.48(1), JPN6022042297, 1999, pages 109 - 116, ISSN: 0005224228 *
HICKEY, JAMES L.; JAMES, JANINE L.; HENDERSON, CLARE A.; PRICE, KATHERINE A.; MOT, ALEXANDRA I.; BUN: "Intracellular Distribution of Fluorescent Copper and Zinc Bis(thiosemicarbazonato) Complexes Measure", INORGANIC CHEMISTRY, vol. Vol.54(19), JPN6022042291, 2015, pages 9556 - 9567, ISSN: 0005224224 *
WARREN, LARRY E.; BURSEY, MAURICE M.; HATFIELD, WILLIAM E.: "Mass spectra of some copper(II) complexes related to anticarcinogens", ORGANIC MASS SPECTROMETRY, vol. Vol.5(1), JPN6022042295, 1971, pages 15 - 18, ISSN: 0005224227 *
YOKOYAMA, AKIRA; HOSOTANI, TAKEO; ARANO, YASUSHI; HORIUCHI, KAZUKO: "Development of neutral and bifunctional radiopharmaceuticals using copper-52-dithiosemicarbazone (DT", RADIOISOTOPES, vol. Vol.35(5), JPN6022042302, 1986, pages 249 - 255, ISSN: 0005224226 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024001064A (ja) * 2017-09-01 2024-01-09 オレゴン ステイト ユニバーシティー 治療用金属錯体およびリガンドならびにその作成および使用の方法

Also Published As

Publication number Publication date
US11596651B2 (en) 2023-03-07
CN111278835A (zh) 2020-06-12
AU2018325283B2 (en) 2023-11-16
WO2019046761A1 (en) 2019-03-07
CA3074258A1 (en) 2019-03-07
US20200188430A1 (en) 2020-06-18
IL272895B1 (en) 2025-02-01
JP2024001064A (ja) 2024-01-09
US12403159B2 (en) 2025-09-02
EP3676271A1 (en) 2020-07-08
IL272895A (en) 2020-04-30
US20230172977A1 (en) 2023-06-08
AU2018325283A1 (en) 2020-03-12
IL272895B2 (en) 2025-06-01

Similar Documents

Publication Publication Date Title
US12403159B2 (en) Therapeutic metal complexes and ligands and methods of making and using the same
JP2025102814A (ja) 発毛を調節するための組成物及び方法
JP5112595B2 (ja) 抗炎症活性および抗生物質活性を有する５−ａｓａ誘導体およびこれを用いて疾患を治療する方法
SK9832001A3 (en) Benzoheterocycles and their use as MEK inhibitors
JPH0811729B2 (ja) １−ヒドロキシピリド−２−オン、又はその塩から成る、患者の体内になる毒性レベルの金属を減少させるのに有効な医薬組成物
AU2014351802B2 (en) Mitochondria-targeted dicarbonyl sequestering compounds
US20250282817A1 (en) Compounds for delivering glutathione to a target and methods of making and using the same
US9950987B2 (en) Aspirin derivatives and uses thereof
US11339294B2 (en) Nanoprobe-metal chelator complexes
TW202102478A (zh) 新穎的鐵螯合物
US10953004B2 (en) Combination therapy for proliferative diseases
TWI722106B (zh) 具有抗癌活性之嘌呤化合物
WO2018113758A1 (zh) 一种作为吲哚胺-2，3-双加氧酶抑制剂的砜脒及其制备方法和用途
HK40086070A (zh) 用於调节毛发生长的组合物和方法
US20200207744A1 (en) Dimer compounds, and use in binding toxic repeats of rna
EP2309859A1 (en) Enzyme inhibitors and the use thereof
BR122025013584A2 (pt) Uso de derivados de mononucleotídeo de nicotinamida
JP2011190257A (ja) 組織線維化疾患の予防または治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230927

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231016

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250918